4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-426878
Chief Executive Officer sold 47,837 shares at $49.78 ($2,381,326)
- Chief Executive Officer acquired 100,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-10-16 | Exercise or conversion : show line 1 in the form | +100,000 | 359,736 | D | ||
| 2026-10-19 | Sale : show line 2 in the form | −47,837 | $49.78 | $2,381,326 | 311,899 | D |
| Open-market sales · 47,837 sh · avg $49.78 · $2,381,326 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-10-16 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −100,000 | 200,000 | D |
Loading xslF345X06/ownership.xml…